A Revolutionary Approach to Treatment of Complex Diseases
Cellular Nanoparticle Platform Technology
Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP™) technology to develop nano-therapeutics. Cellics’ dynamic nanoplatform, Cellular Nanosponges, harnesses the power of cell membranes to craft specialized nanoparticle-based therapeutics. Derived from a variety of wild-type or engineered human cells, the CNP™ technology has the potential to address a broad range of diseases. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang.
Cellular Nanosponge Platform
The Cellular Nanosponge platform includes a supportive nanoparticle core that is coated intact with wild-type or engineered cell membrane. The resulting nanostructure retains the surface protein receptors from the cell membrane, which mirrors innate cells, and can therefore serve as a decoy to bind and neutralize bacterial toxins, cytokines and viruses.